---
title: "MSGE: Fiscal 2026 revenues rose 13% to $1.1B, with adjusted operating income up 18% year-over-year"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295659179.md"
description: "Fiscal 2026 saw 13% revenue growth to $1.1 billion and an 18% rise in adjusted operating income, driven by strong event demand and record Christmas Spectacular sales. Q4 revenues jumped 27% year-over-year, and management projects continued growth in fiscal 2027.Original document: Madison Square Garden Entertainment Corp. [MSGE] SEC 8-K Current Report — Aug. 12 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-12T11:40:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295659179.md)
  - [en](https://longbridge.com/en/news/295659179.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295659179.md)
generator: "portal-rs"
---

# MSGE: Fiscal 2026 revenues rose 13% to $1.1B, with adjusted operating income up 18% year-over-year

Fiscal 2026 saw 13% revenue growth to $1.1 billion and an 18% rise in adjusted operating income, driven by strong event demand and record Christmas Spectacular sales. Q4 revenues jumped 27% year-over-year, and management projects continued growth in fiscal 2027.

Original document: Madison Square Garden Entertainment Corp. \[MSGE\] SEC 8-K Current Report — Aug. 12 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [MSGE.US](https://longbridge.com/en/quote/MSGE.US.md)

## Related News & Research

- [Madison Square Garden Entertainment posts investor deck highlighting venue portfolio and live events business](https://longbridge.com/en/news/295658821.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [EGTX: Q2 2026 revenue up 23% YoY; U.S. Emcitate launch expected Q4 2026 pending FDA approval](https://longbridge.com/en/news/296636890.md)
- [DE: 3Q 2026 saw sales and profit growth, but FY 2026 guidance signals industry headwinds](https://longbridge.com/en/news/296475895.md)
- [Is Samsung’s $72B payout a vote of confidence in AI?](https://longbridge.com/en/news/296469504.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**